JH004

Search documents
嘉应制药股价微跌1.44%,签约多款创新药项目加速布局
Jin Rong Jie· 2025-08-06 17:55
Core Viewpoint - The stock price of Jiaying Pharmaceutical is reported at 6.86 yuan, reflecting a decrease of 0.10 yuan or 1.44% from the previous trading day, with a trading volume of 0.62 billion yuan [1] Company Overview - Jiaying Pharmaceutical operates in the traditional Chinese medicine sector, focusing on the research, development, production, and sales of traditional Chinese medicine and chemical drugs [1] - The company has been advancing a dual-driven strategy of "traditional Chinese medicine characteristics + chemical drug innovation," enhancing its product matrix layout [1] Recent Developments - Jiaying Pharmaceutical has recently signed research and development cooperation agreements with multiple institutions, involving antihistamine drug Bilastine tablets and high-end generic drug projects JH002, JH003, and JH004 [1] - Bilastine is primarily used for the treatment of allergic rhinitis and urticaria, while JH003 and JH004 target hyperuricemia/gout and heart failure, respectively, further enriching the company's product line [1] Financial Insights - On the funding side, Jiaying Pharmaceutical experienced a net outflow of 2.5078 million yuan in main funds today, while the net inflow over the past five days was 7.7439 million yuan [1]
签约拿下多个药品项目,嘉应制药加速推进创新发展
Xiao Fei Ri Bao Wang· 2025-08-04 03:56
Group 1 - The core viewpoint of the articles highlights that under the backdrop of increasing health demands from residents, traditional Chinese medicine companies are expanding their development space through innovative research and development [1][2] - Recently, Jia Ying Pharmaceutical signed research and development cooperation agreements with several institutions, aiming to deepen involvement in multiple innovative and generic drug projects [1] - The cooperation includes the technology transfer of the chemical drug Bilastine tablets and the joint development of high-end generic drug projects JH003 and JH004, targeting areas such as hyperuricemia/gout and heart failure [1] Group 2 - This collaboration is a significant implementation of Jia Ying Pharmaceutical's "4+4" strategy, focusing on new drug research and new product introduction as core strategic elements [2] - The company aims to build a product matrix that integrates traditional Chinese medicine innovation with the field of chemical drug generics, leveraging its "Keya" brand advantages in traditional Chinese medicine [2] - Future plans include enhancing the penetration of core categories in hospitals, OTC, and new retail channels, transitioning the "Keya" brand from product output to health solution provision [2]